Skip to content

Integrating Neuroscience, Developmental Psychopathology, and Preventive Interventions: Critical Questions for the Next Generation of Transformative Research » Agenda

Denver, Colorado

Time Event
8:30 a.m. Arrival and Refreshments
9:00 a.m.

Welcome, Overview of Meeting Goals

Christopher Gordon, PhD
Welcome and Introduction

Amy Goldstein, PhD
Overview of Meeting Goals

9:15 a.m.

Session 1: Biological Targets in Prevention Trials: What are Appropriate Targets and How Should They be Assessed?

Raquel Gur, MD, PhD
Implications of genetics for prevention research
Catherine Monk, PhD
Possible biomarkers for intervention studies: Blood, sweat, and hair
Damien Fair, PhD
Studying the brain at rest: Using functional connectivity MRI to examine typical and atypical development
David Olds, PhD
Joan Luby, MD
Christopher Gordon, PhD
11:15 a.m.

Session 2: Designing Prevention Trials with a Neurodevelopmental Perspective

Martin Teicher, MD
Sensitive and silent periods in neurodevelopment for emergence of psychopathology
Barbara Cornblatt, MD
Prevention of mental illnesses
Mary Dozier, PhD
Integration of behavioral and biomarkers for risk in prevention trials
Irwin Sandler, PhD
Patrick Tolan, PhD
Amy Goldstein, PhD
2:15 p.m.

Session 3: Implications of the Next Generation of Prevention Research for Communities at Risk

Holly Moore, PhD
Perspectives in prevention research: The role of preclinical neuroscience research
Manpreet Singh, MD
Risk and protective factors for bipolar disorder: Can we reduce morbidities and promote resilience?
Rachel Yehuda, MD
Acceptability of early pharmacological intervention for PTSD
John Mann, MD
Ron Prinz, PhD
Christopher Sarampote, PhD
4:00 p.m. Next Steps